Epilepsy Diagnosis & Treatment Market Size was valued at USD 2.9 Billion in 2022. The Epilepsy Diagnosis & Treatment market industry is projected to grow from USD 3.33 Billion in 2023 to USD 10.122 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 14.90% during the forecast period (2023 - 2032). A significant increase in the funds and investments available for the creation of new items are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for epilepsy diagnosis & treatment is being driven by the rising number of accidents. The rise in accidents, the high rate of brain injuries, the high rate of post-traumatic epilepsy (PTE) and post-traumatic seizures (PTS) in patients with brain injuries, and the rising  geriatric population all contribute significantly to the  epilepsy market's revenue growth.
Epilepsy or a stroke can result from ailments such as a cough, fever, exhaustion, tissue disruption, and problems with the kidney, liver, and nervous system. This is another reason that is anticipated to increase the need for epilepsy treatment, significantly driving market revenue growth. Antiepileptic drugs (AEDs) remain the most often used treatment method for epilepsy, despite surgery, vagal nerve stimulation, and dietary changes. Presently, more than 20 commercial AEDs are categorized as first-line therapies. The main goal of AED therapy is to totally and minimally control seizures to enable patients to maintain a normal lifestyle. The best way to achieve this would be to employ a manageable dosage schedule with few limitations on concurrent medications. There is little doubt that since the accidental discovery of phenobarbital in 1912—the first widely used anticonvulsant—immense progress has been made toward this goal.
When a single AED is ineffective at controlling seizures, polytherapy—a combination of AEDs—is usually prescribed. The use of new pharmacology to target medications for particular subpopulations of persons with drug-resistant epilepsy is a significant trend in current antiepileptic drug research. Seizures might happen less frequently than once a year or more frequently than once daily. Up to 10% of people  have one seizure in their lifetime; thus, having one does not necessarily mean that someone has epilepsy. The term "epilepsy" refers to two or more unannounced seizures. The estimated prevalence of active epilepsy, defined as ongoing seizures or the requirement for medication, in the general population at any given moment ranges from 4 to 10 per 1000 people. In high-income countries, epilepsy is thought to impact 49 people out of every 100,000 people annually. This rate can reach 139 per 100 000 in low- and middle-income countries. Seizures are controllable. Up to 70% of people with epilepsy may become seizure-free with proper anti-seizure medication. Considering relevant clinical, social, and personal factors, anti-seizure medication should be stopped after two years without seizures. An aberrant electroencephalography (EEG) pattern and a validated seizure etiology are the two most reliable indications of seizure recurrence.
HIV infection increases the risk of seizures, and this increased risk of HIV infection is the causes of the rise in acute symptomatic seizures. In 5–10% of AIDS patients, neurological illnesses are the first symptom, and 90% of autopsies reveal CNS involvement. About 50% of children and 5% of adults with tuberculosis experience acute seizures. Approximately 10% of rabies patients experience seizures. Numerous infections, such as malaria and Japanese B encephalitis, can result in seizures.. Thus, driving the Epilepsy Diagnosis & Treatment market revenue.
The  Epilepsy Diagnosis & Treatment market segmentation, based on type, includes idiopathic, cryptogenic and symptomatic. The symptomatic segment dominated the market, accounting for 35% of market revenue. Epilepsy that develops after a brain injury recognized as having the potential to cause epilepsy is referred to as symptomatic epilepsy. Examples include severe head injuries, brain tumors, strokes, CNS infections, and operations.
The  Epilepsy Diagnosis & Treatment market segmentation, based on diagnosis, includes neurological exams, blood tests and imaging. The blood tests segment dominated the market. The target audience's tastes and preferences have been changing constantly, creating a constant need for products and market services that will help to ensure that the growing demand is satisfied by the supply chain mechanism.
The  Epilepsy Diagnosis & Treatment market segmentation, based on treatment, includes medication and surgery. The medication segment dominated the market due to several important benefits, including fewer drug-drug interactions, fewer potentially fatal side effects, and a less detrimental effect on cognitive processes. Additionally, the increase in epilepsy cases will increase the demand for medications in this market niche.
The  Epilepsy Diagnosis & Treatment market segmentation, based on end users, includes hospitals and clinics. The hospitals generated the most income (70.4%) because of the expansion of the medical infrastructure and the advancement of technology in drug development. These elements are responsible for the epilepsy treatment market's expansion.
Figure 1  Epilepsy Diagnosis & Treatment Market, by End User, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The Asia Pacific Epilepsy Diagnosis & Treatment market will dominate this market, As well as improving healthcare policies and rising disposable income levels in developing nations like China, Japan, and India. The government's spending on drug development and other innovative technologies is rising, driving up market income in this area. Over 10 million people in India have epilepsy.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 Â EPILEPSY DIAGNOSIS & TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Epilepsy Diagnosis & Treatment market accounts for the second-largest market share because of increased government efforts to raise awareness of the problem and accessible therapies and favorable reimbursement scenarios. Further, the German Epilepsy Diagnosis & Treatment market held the largest market share, and the UK Epilepsy Diagnosis & Treatment market was the fastest-growing market in the European region.
The North American Epilepsy Diagnosis & Treatment Market is expected to grow fastest from 2023 to 2032. This is due to the increasing prevalence of epilepsy and market players' strategic initiatives, awareness campaigns, and product launches. The market is expanding due to the approval of medications for various elderly groups. Moreover, US Epilepsy Diagnosis & Treatment market held the largest market share, and the Canada Epilepsy Diagnosis & Treatment market was the fastest-growing market in the North American region.
Epilepsy Diagnosis & Treatment Key Market Players & Competitive Insights
Leading industry companies are making significant R&D investments to diversify their product offerings, which will drive the Epilepsy Diagnosis & Treatment market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants also engage in several strategic actions to increase their worldwide presence. The Epilepsy Diagnosis & Treatment industry must provide affordable products to grow and thrive in a more competitive and challenging market environment.
Local manufacturing to cut operating costs is one of the key business tactics manufacturers use in the  Epilepsy Diagnosis & Treatment industry to help clients and expand the market sector. Major players in the Epilepsy Diagnosis & Treatment market, including LivaNova PLC, and others, are attempting to increase market demand by investing in research and development operations.
With nearly 50 years of experience and tireless dedication to giving patients and their families hope through cutting-edge medical solutions that strengthen both the Head and the Heart, LivaNova PLC is a  leader in medical technology and innovation. With its  headquarters in London, LivaNova employs about 4,000 people and operates in more than 100 nations to benefit patients, medical personnel, and healthcare systems. Cardiovascular and Neuromodulation are the two businesses that make up LivaNova; their respective operating offices are in Houston (USA) and Mirandola (Italy). In November 2019, This November, LivaNova PLC honors National Epilepsy Awareness Month in the US. The business is working to raise awareness of epilepsy, the fourth most prevalent neurological condition that affects more than 65 million individuals worldwide of all ages. To reduce the stigma attached to epilepsy, there is a growing need to raise awareness of the condition, disseminate information about available treatment choices, and boost education.
Pfizer uses research and our extensive resources to develop treatments that help people live longer and significantly better lives. Regarding the research, development, and production of health care goods, they work hard to set the bar for quality, safety, and value. In addition to many of the world's most well-known consumer health care goods, their  range also includes pharmaceuticals and vaccines. In May 2019, -Pfizer Inc. that the primary aim of a Phase 3 study evaluating LYRICA (pregabalin) as supplementary therapy for epilepsy patients aged 5 to 65 with primary generalized tonic-clonic (PGTC) seizures was not met. Contrary to the placebo, taking LYRICA did not statistically significantly reduce the frequency of seizures.
Key Companies in the Epilepsy Diagnosis & Treatment market include
Epilepsy Diagnosis & Treatment Industry Developments
March 2022Â The United States Food and Drug Administration granted Lupin's abbreviated new drug application (ANDA) for Vigabatrin approval. It is an anti-epileptic medication that will be sold as a 500 mg oral solution USP.
March 2022Â The US Food and Medicine Administration has also given the medicine Ztalmy by Marinus Pharmaceuticals permission to treat seizures in people with CDKL5 deficiency, a genetic form of epilepsy.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 2.9 Billion |
| Market Size 2023 | USD 3.33 Billion |
| Market Size 2032 | USD 10.122 Billion |
| Compound Annual Growth Rate (CAGR) | 14.90% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment, End USer and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Â General Mills Inc., Amway, Conagra Brands Inc., Cargill Incorporated, Abbott Laboratories, Kraft Foods Group Inc., The Coca-Cola Company, PepsiCo Inc., Atkins Nutritionals Inc., and Brunswick Corporation |
| Key Market Opportunities | Growing awareness among people |
| Key Market Dynamics | Increase in health difficulties and worries |
Epilepsy Diagnosis Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The Epilepsy Diagnosis & Treatment market size was valued at USD 2.9 Billion in 2022.
The market is projected to grow at a CAGR of 14.90% during the forecast period, 2023-2032.
Asia Pacific had the largest share in the market
The key players in the market are Pfizer, Inc. (US),Siemens Ltd. (Germany),Johnson & Johnson Services, Inc. (US),UCB Pharma Ltd. (UK),Natus Medical Incorporated. (US),Shire (Republic of Ireland),Abbott (US),NeuroWave Systems Inc. (US)).
The medication category dominated the market in 2022.
The hospital had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
